Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Sequus Pharmaceuticals Inc.

(SEQU), Menlo Park, Calif.

Business: Cancer

Hanifen, Imhoff analyst Robert Swift rated SEQ "underperform" based on his

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE